DGAP-News: Epigenomics AG / Key word(s): Statement/Capital Increase
04.11.2019 / 20:55
Epigenomics AG: No operational reasons for sharp decline in share price
Berlin (Germany) and San Diego, CA (U.S.A.), 4 November, 2019 – The Epigenomics share price today recorded a decline of around 16% with high trading volumes, closing at a price of EUR 0.93 on the XETRA exchange. The management of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the “company”) makes it clear that there are no operational reasons for the current and inexplicable price decline.
Greg Hamilton, CEO of Epigenomics AG: “We are very surprised by today’s share price performance. From an operational point of view, there are no reasons to justify the price decline. In fact, the opposite is true. We eagerly await the summary presentation of the positive results of the microsimulation model at the 12th European Public Health Conference of the European Public Health Association on 21 November, 2019 and we continue to expect publication in a peer-reviewed journal to follow. The discussions with our institutional investors in connection with the capital increase have also been positive so far. We expect the current capital raise initiative to be successful.”
Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics’ lead product, Epi proColon(R), is a blood-based screening test for the detection of colorectal cancer. Epi proColon has received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in the United States, Europe, and China and selected other countries. Epi proLung(R), a blood-based test for lung cancer detection, and HCCBloodTest, a blood-based test for liver cancer detection in cirrohtic patients, have received CE mark in Europe.
For more information, visit www.epigenomics.com.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Phone:||+49 30 24345-0|
|Fax:||+49 30 24345-555|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||904207|
|End of News||DGAP News Service|